Stockreport

Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise

Erasca, Inc.  (ERAS) 
PDF Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib plus trametinib reinforce therapeutic potential in NRASm melanoma and further support ongoing Phase 3 SEACR [Read more]